• SENSEX
    NIFTY 50
Healthcare

COVID-19 vaccine tracker | From Pfizer to Moderna, a look at the progress made by pharma companies so far

Updated : 2020-11-19 17:26:14

Although no vaccine has been 100 percent effective in eliminating the COVID-19 virus, here's a look at the progress pharma companies have made on the vaccine front so far.

As the battle against the COVID-19 virus continues, pharmaceutical companies are racing against time to develop a vaccine that could save millions of people from the deadly outbreak. Although no vaccine has been 100 percent effective in eliminating the COVID-19 virus, here's a look at the progress pharma companies have made on the vaccine front so far. (Image: AP Photo)
As the battle against the COVID-19 virus continues, pharmaceutical companies are racing against time to develop a vaccine that could save millions of people from the deadly outbreak. Although no vaccine has been 100 percent effective in eliminating the COVID-19 virus, here's a look at the progress pharma companies have made on the vaccine front so far. (Image: AP Photo)
Pfizer-BioNTech | Pfizer Inc announced that the COVID-19 vaccine developed in partnership with BioNTech was found to be 95 percent effective in the final analysis of the Phase 3 trial. (Image: Reuters)
Pfizer-BioNTech | Pfizer Inc announced that the COVID-19 vaccine developed in partnership with BioNTech was found to be 95 percent effective in the final analysis of the Phase 3 trial. (Image: Reuters)
Moderna Therapeutics | The Massachusetts-based firm that developed the mRNA-1273 jointly with the National Institute of Health is reporting good preliminary data from Phase 3 trials. (Image: Reuters)
Moderna Therapeutics | The Massachusetts-based firm that developed the mRNA-1273 jointly with the National Institute of Health is reporting good preliminary data from Phase 3 trials. (Image: Reuters)
Bharat Biotech | Phase three trials of Covaxin, the vaccine candidate being developed indigenously by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), will begin on Friday. (Image: Reuters)
Bharat Biotech | Phase three trials of Covaxin, the vaccine candidate being developed indigenously by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), will begin on Friday. (Image: Reuters)
Sinovac Biotech | Results from the early-phase clinical trial of the Chinese vaccine candidate CoronaVac, revealed that the formulation appears safe and induces an antibody response in healthy volunteers aged between 18 and 59 years. (Image: Reuters)
Sinovac Biotech | Results from the early-phase clinical trial of the Chinese vaccine candidate CoronaVac, revealed that the formulation appears safe and induces an antibody response in healthy volunteers aged between 18 and 59 years. (Image: Reuters)
Sinopharm | China National Pharmaceutical Group (Sinopharm) said last week that data from large-scale, late-stage clinical trials for its COVID-19 vaccine are
Sinopharm | China National Pharmaceutical Group (Sinopharm) said last week that data from large-scale, late-stage clinical trials for its COVID-19 vaccine are "better than expected". (Image: Reuters)
Sputnik V | Russia has resumed vaccination of new volunteers in its trial for the flagship COVID-19 Sputnik V vaccine, developed by Gamaleya Institute, after a short pause as Moscow moved to accelerate plans to inoculate the population. (Image: Reuters)
Sputnik V | Russia has resumed vaccination of new volunteers in its trial for the flagship COVID-19 Sputnik V vaccine, developed by Gamaleya Institute, after a short pause as Moscow moved to accelerate plans to inoculate the population. (Image: Reuters)
Johnson & Johnson | The multinational’s Janssen Pharmaceuticals division is under the process of developing a vaccine called JNJ-78436735. (Image: AP Photo)
Johnson & Johnson | The multinational’s Janssen Pharmaceuticals division is under the process of developing a vaccine called JNJ-78436735. (Image: AP Photo)
Oxford University and AstraZeneca | The coronavirus vaccine developed by teams at the University of Oxford, being manufactured by pharma major AstraZeneca, has shown to trigger a robust immune response in healthy adults aged between 56 and 69, and those over 70 years of age. (Image: Reuters)
Oxford University and AstraZeneca | The coronavirus vaccine developed by teams at the University of Oxford, being manufactured by pharma major AstraZeneca, has shown to trigger a robust immune response in healthy adults aged between 56 and 69, and those over 70 years of age. (Image: Reuters)
CanSino Biologics | Mexico has received doses of a COVID-19 vaccine candidate from Chinese pharmaceutical company CanSino Biologics Inc for late stage-trial on 10,000 and 15,000 volunteers. (Image: Reuters)
CanSino Biologics | Mexico has received doses of a COVID-19 vaccine candidate from Chinese pharmaceutical company CanSino Biologics Inc for late stage-trial on 10,000 and 15,000 volunteers. (Image: Reuters)
Novavax | In late-phase clinical development, the Novavax COVID-19 vaccine candidate, NVX-CoV2373, is a stable, prefusion protein that can be used to elicit robust neutralising antibody responses. (Image: Reuters)
Novavax | In late-phase clinical development, the Novavax COVID-19 vaccine candidate, NVX-CoV2373, is a stable, prefusion protein that can be used to elicit robust neutralising antibody responses. (Image: Reuters)
Murdoch Children's Research Institute | The largest health research institute in Australia has begun trials to see if it's Bacillus Calmette-Guérin (BCG) vaccine can successfully fight off the virus. (Image: Reuters)
Murdoch Children's Research Institute | The largest health research institute in Australia has begun trials to see if it's Bacillus Calmette-Guérin (BCG) vaccine can successfully fight off the virus. (Image: Reuters)
Live TV

recommended for you

Ask Our Experts CNBC TV18

Advertisement